ARTICLE | Clinical News
Tazemetostat: Phase II started
January 25, 2016 8:00 AM UTC
Epizyme began an open-label, international Phase II trial to evaluate 800 mg oral tazemetostat twice daily in about 90 adult patients. The first cohort will comprise patients with malignant rhabdoid t...